Publicaciones en las que colabora con María Dolores Caballero Barrigón (11)

2021

  1. Allogeneic Stem Cell Transplantation in Mature T Cell and Natural Killer/T Neoplasias: A Registry Study from Spanish GETH/GELTAMO Centers

    Transplantation and Cellular Therapy, Vol. 27, Núm. 6, pp. 493.e1-493.e8

  2. Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study

    Bone Marrow Transplantation, Vol. 56, Núm. 8, pp. 1919-1928

2019

  1. Response to Novel Drugs before and after Allogeneic Stem Cell Transplantation in Patients with Relapsed Multiple Myeloma

    Biology of Blood and Marrow Transplantation, Vol. 25, Núm. 9, pp. 1703-1712

2017

  1. Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation

    Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380

  2. Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial

    Biology of Blood and Marrow Transplantation, Vol. 23, Núm. 1, pp. 53-59

2015

  1. Fungal and viral infections after allogeneic hematopoietic transplantation from unrelated donors in adults: Improving outcomes over time

    Bone Marrow Transplantation, Vol. 50, Núm. 2, pp. 274-281

2013

  1. Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients

    British Journal of Haematology, Vol. 162, Núm. 4, pp. 474-482

2011

  1. Long-term results of fludarabine/melphalan as a reduced-intensity conditioning regimen in mantle cell lymphoma: The GELTAMO experience

    Therapeutic Advances in Hematology, Vol. 2, Núm. 1, pp. 5-10

2010

  1. Unrelated Transplantation for Poor-Prognosis Adult Acute Lymphoblastic Leukemia: Long-Term Outcome Analysis and Study of the Impact of Hematopoietic Graft Source

    Biology of Blood and Marrow Transplantation, Vol. 16, Núm. 7, pp. 957-966

2008

  1. Reduced-Intensity Conditioning Allogeneic Transplantation from Unrelated Donors: Evaluation of Mycophenolate Mofetil Plus Cyclosporin A as Graft-versus-Host Disease Prophylaxis

    Biology of Blood and Marrow Transplantation, Vol. 14, Núm. 6, pp. 664-671

1997

  1. Trasplante autólogo con esquema BEAM en linfoma

    Sangre, Vol. 42, Núm. SUPPL. 1, pp. 46-49